Long Focus Capital Management’s Oncolytics Biotech ONCY Stock Holding History

Long Focus Capital Management’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,000	Closed	-$34.8K	–	113
2024 Q3	$34.8K	Hold	40,000	–	–	﹤0.01%	100
2024 Q2	$39.6K	Hold	40,000	–	–	﹤0.01%	101
2024 Q1	$42.4K	Hold	40,000	–	–	﹤0.01%	98
2023 Q4	$54K	Hold	40,000	–	–	﹤0.01%	109
2023 Q3	$87.2K	Hold	40,000	–	–	﹤0.01%	110
2023 Q2	$104K	Hold	40,000	–	–	﹤0.01%	108
2023 Q1	$48K	Hold	40,000	–	–	﹤0.01%	113
2022 Q4	$65.2K	Hold	40,000	–	–	﹤0.01%	107
2022 Q3	$49K	Hold	40,000	–	–	﹤0.01%	105
2022 Q2	$40K	Hold	40,000	–	–	﹤0.01%	111
2022 Q1	$63K	Hold	40,000	–	–	0.01%	106
2021 Q4	$56K	Buy	+40,000	New	+$73.9K	0.01%	103

Other funds holding ONCY

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Long Focus Capital Management's ONCY Position: Q4 2024 in Review

Long Focus Capital Management sold out of Oncolytics Biotech (ONCY) in Q4 2024, closing a stake of 40,000 shares — an estimated $34.8K sold.

Long Focus Capital Management first reported a position in ONCY in Q4 2021 and held it in 12 quarters. The position peaked at $104K in Q2 2023. 46 funds tracked by Wall St. Rank hold ONCY as of Q4 2024.

Long Focus Capital Management reported no remaining Oncolytics Biotech position as of Q4 2024 after selling out during the quarter.
Long Focus Capital Management sold 40,000 Oncolytics Biotech shares in Q4 2024, an estimated $34.8K.
Long Focus Capital Management first reported a position in Oncolytics Biotech in Q4 2021 and held it in 12 quarters.
Long Focus Capital Management's Oncolytics Biotech position peaked at $104K in Q2 2023.
46 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2024.

Based on Long Focus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.